文献速递胸部肿瘤

利用分子亚型脆弱性识别合理联合治疗——广泛期小细胞肺癌的下一个浪潮?

Leveraging Vulnerabilities of Molecular Subtypes to Identify Rational Combination Therapies-The Next Wave in Extensive-Stage SCLC?
PubMed 文献 · J Thorac Oncol · 2026-01-01

广泛期小细胞肺癌一线以铂类-依托泊苷联合抗PD-L1抑制剂为基础,但多数患者出现难治性疾病。Ponce等研究在临床前模型发现lurbinectedin与伊立替康在特定分子亚型中协同抗肿瘤,并在26例复发SCLC的I-II期剂量递增研究中测试该联合。本述评讨论患者来源异种移植、协同组合、最佳序贯及生物标志物指导的患者选择等主题。

要点

  • 广泛期SCLC一线标准为铂类-依托泊苷联合抗PD-L1抑制剂,但多数患者最终难治。
  • lurbinectedin联合伊立替康在特定分子亚型临床前模型中显示协同抗肿瘤活性。
  • 该联合在26例复发SCLC的I-II期剂量递增研究中进行了早期临床测试。

核心结论

  • lurbinectedin与伊立替康联合在特定分子亚型SCLC临床前模型中显示协同抗肿瘤活性,并在复发SCLC的I-II期研究中完成早期测试。

研究设计与样本

  • Ponce等开展临床前研究,并在26例复发SCLC患者中进行I-II期剂量递增研究,测试lurbinectedin联合伊立替康。

主要发现

  • 临床前模型显示lurbinectedin与伊立替康在特定分子亚型SCLC中诱导协同抗肿瘤活性。

关键数值与推荐

  • 广泛期SCLC一线治疗基础为铂类-依托泊苷双药联合抗PD-L1抑制剂。
  • 复发SCLC的I-II期剂量递增研究纳入26例患者。

临床怎么用

  • 述评强调患者来源异种移植、协同组合、最佳序贯治疗及包括神经内分泌亚型生物标志物指导的患者选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current landscape of extensive-stage SCLC treatment is dynamic, with exciting active agents including bispecific T-cell engagers, antibody-drug conjugates, and novel combinations. The foundation of SCLC frontline treatment is platinum-etoposide doublet plus anti-PD-L1 inhibitor, but most patients will develop refractory disease. Identifying effective treatments with manageable toxicity remains a major unmet clinical need. The study by Ponce et al, entitled "Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients," made significant contributions to the field. This study revealed that lurbinectedin and irinotecan induced synergistic antitumor activity in specific molecular subtypes of SCLC in preclinical models and then tested this combination in a phase I-II dose-escalation study in 26 patients with relapsed SCLC. This commentary will discuss how this work highlighted several impactful themes in SCLC: (1) innovative use of patient-derived xenografts; (2) synergistic combinations; (3) optimal sequencing of therapies; and (4) appropriate patient selection including the potential for biomarker-directed option for neuroendocrine subtypes.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Sethakorn N, Chiang AC. Leveraging Vulnerabilities of Molecular Subtypes to Identify Rational Combination Therapies-The Next Wave in Extensive-Stage SCLC? J Thorac Oncol. 2026. PMID: 42399012. doi:10.1016/j.jtho.2026.103898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。